Project Details
| Short title | D3L-001-100 |
|---|---|
| Acronym | D3L-001-100 |
| Status | Active |
| Effective start/end date | 4/04/24 → 19/03/29 |
CTU: A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects with HER2-Positive Advanced Solid Tumors.
- Park, John (Primary Chief Investigator)
- Chester, Catherine (Clinical Trial Unit Staff)
- Chapman, Nicola (Clinical Trial Unit Staff)
- TAIDI, Gina (Clinical Trial Unit Staff)
- Martin, Lewis (Clinical Trial Unit Staff)
Project: Research